Ipsen réalise une croissance remarquable des ventes au cours des neuf premiers mois de 2026 et relève à nouveau ses prévisions pour l’exercice en cours

Ipsen reported 24.6% revenue growth at constant exchange rates for the first nine months of 2026, exceeding expectations and prompting the company to raise its full-year guidance. The group now projects approximately 23.0% revenue growth and 39.0% operating margin for 2026. Growth was driven by its strategic portfolio, particularly Somatuline, alongside progress in its R&D pipeline with advanced-stage assets in oncology, rare diseases, and neurosciences showing blockbuster potential.